Calvin Santiago, MD, FRCPC, MSc (he/him)
Clinical Assistant Professor, Neurology & Neurological Sciences
Bio
Dr. Santiago is a board-certified neurologist with Stanford Health Care. He is a clinical assistant professor in the Department of Neurology and Neurological Sciences, Division of Comprehensive Neurology at Stanford University School of Medicine.
Dr. Santiago diagnoses and treats a wide range of neurological conditions, including headache, epilepsy, memory disorders, movement disorders, and neuropathy. He has a special focus on improving access to neurological care, including reducing patient wait times and directing patients to the most appropriate care provider by streamlining physician referrals. He also provides LGBTQ+ care.
His research interests include executive functioning and processing speed in older adults with coronary artery disease and using CT angiography in patients with acute ischemic stroke and transient ischemic attack. He has also researched speech-language changes in patients with mild cognitive impairment and Alzheimer’s disease.
Dr. Santiago has published in multiple peer-reviewed journals, including Alzheimer’s Research & Therapy, Alzheimer’s & Dementia, and Cureus: Journal of Medical Science. He has presented to his peers at national and regional meetings, including the Society of Biological Psychiatry Annual Meeting, History of Medicine Days at the University of Calgary, and the Advanced Learning in Palliative Medicine Conference at the University of Toronto.
Dr. Santiago is a member of the American Academy of Neurology, Canadian Neurological Sciences Foundation, and Ontario Medical Association.
Clinical Focus
- Neurology
Honors & Awards
-
Undergraduate Palliative Care Narrative Award, Canadian Society of Palliative Care Physicians
-
Heart & Stroke Foundation of Ontario Graduate Scholarships in Science and Technology Award, University of Toronto
-
Postgraduate Medical Education (PGME) Leadership Certificate Program, University of Toronto
-
Dr. William Whitelaw Award, History of Medicine Days Conference, University of Calgary
-
Canadian Institutes of Health Research (CIHR) Institute Community Support (ICS) Travel Award, Young Investigators Forum
-
Associated Medical Sciences/Boyd Upper Award, Queen’s University
Professional Education
-
Board Certification: Royal College of Physicians and Surgeons of Canada, Neurology (2023)
-
Residency: University of Toronto Faculty of Medicine (2023) Canada
-
Medical Education: Queen's University School of Medicine (2018) Canada
-
Masters of Science, University of Toronto, Toronto, Canada (2014)
All Publications
-
Correlating natural language processing and automated speech analysis with clinician assessment to quantify speech-language changes in mild cognitive impairment and Alzheimer's dementia.
Alzheimer's research & therapy
2021; 13 (1): 109
Abstract
Language impairment is an important marker of neurodegenerative disorders. Despite this, there is no universal system of terminology used to describe these impairments and large inter-rater variability can exist between clinicians assessing language. The use of natural language processing (NLP) and automated speech analysis (ASA) is emerging as a novel and potentially more objective method to assess language in individuals with mild cognitive impairment (MCI) and Alzheimer's dementia (AD). No studies have analyzed how variables extracted through NLP and ASA might also be correlated to language impairments identified by a clinician.Audio recordings (n=30) from participants with AD, MCI, and controls were rated by clinicians for word-finding difficulty, incoherence, perseveration, and errors in speech. Speech recordings were also transcribed, and linguistic and acoustic variables were extracted through NLP and ASA. Correlations between clinician-rated speech characteristics and the variables were compared using Spearman's correlation. Exploratory factor analysis was applied to find common factors between variables for each speech characteristic.Clinician agreement was high in three of the four speech characteristics: word-finding difficulty (ICC = 0.92, p<0.001), incoherence (ICC = 0.91, p<0.001), and perseveration (ICC = 0.88, p<0.001). Word-finding difficulty and incoherence were useful constructs at distinguishing MCI and AD from controls, while perseveration and speech errors were less relevant. Word-finding difficulty as a construct was explained by three factors, including number and duration of pauses, word duration, and syntactic complexity. Incoherence was explained by two factors, including increased average word duration, use of past tense, and changes in age of acquisition, and more negative valence.Variables extracted through automated acoustic and linguistic analysis of MCI and AD speech were significantly correlated with clinician ratings of speech and language characteristics. Our results suggest that correlating NLP and ASA with clinician observations is an objective and novel approach to measuring speech and language changes in neurodegenerative disorders.
View details for DOI 10.1186/s13195-021-00848-x
View details for PubMedID 34088354
View details for PubMedCentralID PMC8178861
- The Nervous System Essentials of Clinical Examination edited by Ahmed, J., Basu, M., Gosse, P., Vinette, S., Santiago, C., Izenberg, A. 2021; 9
-
Patient Outcomes With Use of Computed Tomography Angiography in Acute Ischemic Stroke and Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Cureus
2020; 12 (5): e8187
Abstract
Objectives It remains uncertain whether computed tomography angiography (CTA) in ischemic strokes and transient ischemic attacks (TIAs) benefits patient outcomes beyond those eligible for endovascular therapy. We conducted a systematic review and meta-analysis of observational studies and randomized controlled trials (RCTs) investigating the use of CTA against other imaging modalities for recurrent stroke, mortality, disability, emergency department (ED) revisits, or changes in management in ischemic stroke and TIA. (PROSPERO: 349590) Methods MEDLINE, Embase, and CENTRAL were searched. We included studies evaluating CTA against non-CTA imaging modalities for outcomes of interest in ischemic stroke or TIA. Two reviewers extracted data and assessed study quality. Data were pooled by the generic inverse variance method. Heterogeneity was assessed using Cochran's Q statistic and quantified by I2. Quality of the evidence was assessed by GRADE. Results We found 12 eligible cohort studies involving 17,481 patients, and no eligible RCTs. No changes were detected in recurrent stroke, mortality, or disability when CTA was compared against pooled imaging modalities, nor compared to non-contrast computed tomography (NCCT) alone. The evidence for each outcome was graded as low quality to very low quality. Conclusions CTA use was not associated with significant reductions in recurrent stroke, mortality, or disability in ischemic stroke and TIA patient compared with other imaging modalities. More high-quality studies are needed.
View details for DOI 10.7759/cureus.8187
View details for PubMedID 32566428
View details for PubMedCentralID PMC7301443
- A comparison of clinician assessment of speech versus automated speech analysis in mild cognitive impairment and Alzheimer’s dementia Alzheimer’s & Dementia 2020
-
Three.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
2019; 191 (19): E537-E538
View details for DOI 10.1503/cmaj.190091
View details for PubMedID 31085565
View details for PubMedCentralID PMC6520070
-
Subcortical hyperintensities in the cholinergic system are associated with improvements in executive function in older adults with coronary artery disease undergoing cardiac rehabilitation.
International journal of geriatric psychiatry
2018; 33 (2): 279-287
Abstract
Coronary artery disease (CAD) is frequently accompanied by white matter hyperintensities and executive dysfunction. Because acetylcholine is important in executive function, these symptoms may be exacerbated by subcortical hyperintensities (SH) located in cholinergic (CH) tracts. This study investigated the effects of SH on cognitive changes in CAD patients undergoing a 48-week cardiac rehabilitation program.Fifty patients (age 66.5 ± 7.1 years, 84% male) underwent the National Institute of Neurological Disorders and Stroke - Canadian Stroke Network neurocognitive battery at baseline and 48 weeks. Patients underwent a 48-week cardiac program and completed neuroimaging at baseline. Subcortical hyperintensities in CH tracts were measured using Lesion Explorer. Repeated measures general linear models were used to examine interactions between SH and longitudinal cognitive outcomes, controlling for age, education, and max VO2 change as a measure of fitness.In patients with SH in CH tracts, there was a significant interaction with the Trail Making Test (TMT) part A and part B over time. Patients without SH improved on average 16.6 and 15.0% on the TMT-A and TMT-B, respectively. Patients with SH on average showed no improvements in either TMT-A or TMT-B over time. There were no significant differences in other cognitive measures.These results suggest that CAD patients with SH in CH tracts improve less than those without SH in CH tracts, over 48 weeks of cardiac rehabilitation. Thus, SH in CH tracts may contribute to longitudinal cognitive decline following a cardiac event and may represent a vascular risk factor of cognitive decline. © 2017 The Authors. International Journal of Geriatric Psychiatry Published by John Wiley & Sons Ltd.
View details for DOI 10.1002/gps.4729
View details for PubMedID 28474775
View details for PubMedCentralID PMC5811800
-
White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
2015; 23 (7): 754-63
Abstract
Coronary artery disease (CAD) is associated with an increased risk of cognitive decline. Although cerebral white matter (WM) damage predicts cognitive function in CAD, conventional neuroimaging measures only partially explain the effect of CAD on cognition. The purpose of this study was to determine if WM microstructural integrity and CAD using diffusion tensor imaging (DTI) correlates with cognitive function in older adults with CAD.Forty-nine CAD patients (66 ± 7 years old, 86% male) underwent neurocognitive assessments using the cognitive battery recommended by the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network for the study of vascular cognitive impairment. Composite scores for each cognitive domain were calculated. Microstructural integrity in normal-appearing WM was quantified as fractional anisotropy (FA) using DTI in nine bilateral and two interhemispheric WM tracts from the Johns Hopkins University WM Tractography Atlas. Linear regression models examined associations between FA and cognitive performance, controlling for age, sex, and education, with correction for multiple comparisons using a false discovery rate of 5%.Executive function was most significantly associated with FA in the left parahippocampal cingulum (β = 0.471, t = 3.381, df = 44, p = 0.002) and left inferior fronto-occipital fasciculus (β = 0.430, t = 2.984, df = 44, p = 0.005). FA was not associated with memory in any of the WM tracts examined.These results suggest that WM microstructural integrity may be an important neural correlate of executive function even in cognitively intact CAD patients. This study suggests WM damage may be relevant to subtle cognitive decline in a population that may have early neural risk for dementia.
View details for DOI 10.1016/j.jagp.2014.09.008
View details for PubMedID 25499674
-
Druggability of methyl-lysine binding sites.
Journal of computer-aided molecular design
2011; 25 (12): 1171-8
Abstract
Structural modules that specifically recognize--or read--methylated or acetylated lysine residues on histone peptides are important components of chromatin-mediated signaling and epigenetic regulation of gene expression. Deregulation of epigenetic mechanisms is associated with disease conditions, and antagonists of acetyl-lysine binding bromodomains are efficacious in animal models of cancer and inflammation, but little is known regarding the druggability of methyl-lysine binding modules. We conducted a systematic structural analysis of readers of methyl marks and derived a predictive druggability landscape of methyl-lysine binding modules. We show that these target classes are generally less druggable than bromodomains, but that some proteins stand as notable exceptions.
View details for DOI 10.1007/s10822-011-9505-2
View details for PubMedID 22146969